164
Participants
Start Date
November 30, 2017
Primary Completion Date
December 23, 2019
Study Completion Date
January 10, 2020
XADAGO (safinamide)
XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
Neurological Associates of Long Island, PC, Lake Success
NYU Winthrop Hospital, Mineola
Neurology and Stroke Associates, Lititz
Georgetown University Hospital, Washington D.C.
Inova Medical Group- Neurology I, Alexandria
Meridian Clinical Research, LLC, Norfolk
FryeCare Neurology, Hickory
Prisma Health, Greenville
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
Parkinson's Disease Treatment Center of SW Florida, Port Charlotte
Neuron Research, Naples
Sarasota Memorial Hospital Clinical Research Cener, Sarasota
Alabama Neurology Associates, Homewood
Baptist Health System, Richmond
Dayton Center for Neurological Disorders, Centerville
Central DuPage Hospital, Winfield
Lester and Cox Medical Center, Springfield
University of Kansas Medical Center, Kansas City
Southeast Neuroscience Center, LLC, Gray
The Movement Disorder Clinic of Oklahoma, Tulsa
Texas Institute for Neurological Disorders, Sherman
Baylor Scott and White Health, Temple
Houston Methodist - Sugar Land, Sugar Land
Covenant Medical Group, Lubbock
B.E.S.T. Center of Orange County, Laguna Hills
Movement Disorders Neurology, Inc., Bakersfield
Valley Parkinson Clinic, Los Gatos
UC Davis Medical Center, Sacramento
Puget Sound Neurology, Tacoma
Hartford Healthcare, Vernon
Supernus Pharmaceuticals, Inc.
INDUSTRY